MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Diagnostics Arena Changing, For Better and Worse

Article-Diagnostics Arena Changing, For Better and Worse

This morning's New York Times has an extensive article on the new wave of genomic-based diagnostic tests. The new territories they can explore in diagnostics are exhilarating, and their profit margins are far more than those for conventional tests. But concerns remain about whether the extra cost is justified, and FDA is interested in expanding its regulatory oversight. Traditionally, FDA has regulated tests sold to doctors and hospitals but not those done by a single lab.

This will have to be looked at on a case-by-case basis, though. For every genomic-based test that's nothing more than an excuse to pad profits, there will probably be several that represent real improvement, saving costs in the long run.    

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.